English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/100140
logo share SHARE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Metabolomics in the study of alzheimer's disease

AuthorsIbáñez, Clara ; Valdés, Alberto ; García-Cañas, Virginia ; Simó, Carolina
KeywordsMass spectrometry
Alzheimer's disease
Issue Date2014
CitationComprehensive Analytical Chemistry 64(Cap.10): 249-278 (2014)
AbstractWith an increasing aging population, Alzheimer's disease (AD) has become a social and economic problem to societies worldwide, affecting millions of people. However, pathophysiological events associated with AD are not well elucidated yet, and current definitive diagnosis is only obtained after death through examination of brain tissue. In the last years, Metabolomics has been demonstrated to provide deep insights into the full complexity of the disease phenotype and has been established as a promising approach to provide disease-specific metabolite signatures. The incipient application of Metabolomics may potentially contribute in the elucidation of AD physiopathological processes and ideally may offer therapeutic/preventing mechanisms to slow or reverse AD progress. In this chapter, nontargeted metabolomic approaches applied to AD investigation are described. © 2014 Elsevier B.V.
Publisher version (URL)http://dx.doi.org/10.1016/B978-0-444-62650-9.00010-5
Identifiersdoi: 10.1016/B978-0-444-62650-9.00010-5
isbn: 978-0-444-62650-9
Appears in Collections:(CIAL) Libros y partes de libros
Files in This Item:
File Description SizeFormat 
ChapterMetabolomics in the study.pdf5,42 MBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.